Home LiteratureArticle Details
PMID: 9369349 Published · ppublish English Journal Article

Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin.

European journal of pharmacology ·Vol. 334 ·No. 2-3 ·1997-09-10 ·Pages 201-7

De Gennaro Colonna V, Rossoni G, Bernareggi M, Müller EE, Berti F

Abstract

The ability of hexarelin, an effective growth hormone (GH)-releasing hexapeptide, to reverse the worsening of cardiac dysfunction in GH-deficient animals was studied in young male rats passively immunized by administration of an anti-GH-releasing hormone (GHRH) serum. Heart preparations from anti-GHRH serum-treated rats, undergoing low-flow ischemia and reperfusion, showed: (1) a progressive increase of left ventricular end-diastolic pressure during the ischemic period and a poor recovery of contractility at reperfusion with a consistent decrease of the left ventricular-developed pressure; (2) a decreased rate of formation of 6-keto-prostaglandin F1alpha (6-keto-PGF1alpha), a stable metabolite of prostacyclin, in perfusates from preischemic and reperfusion periods; (3) an increased vasopressor activity of angiotensin II. Hexarelin (80 microg/kg, bid, s.c.), administered for 15 days to anti-GHRH serum-treated rats, restored to normal the impaired somatotropic function and counteracted the ischemic damage, improving postischemic left ventricular developed pressure to values higher than those of controls. Furthermore, both the generation of 6-keto-PGF1alpha and the vasopressor activity of angiotensin II reverted to those of control preparations. Administration of hexarelin to control rats induced a considerable improvement of postischemic ventricular function of the perfused hearts which was similar to that present in preparations from anti-GHRH serum-treated rats given hexarelin. This protective activity was divorced from any further stimulation of somatotropic function. Collectively, these data indicate that, in GH-deficient rats, hexarelin is capable of restoring somatotropic function and has a beneficial effect in myocardial ischemia and reperfusion damage. In addition, the increased responsiveness of the coronary vasculature to angiotensin II and the decreased generation of prostacyclin in hearts from GH-deficient rats would indicate that for prevention of injury and dysfunction of the vascular endothelium a normal somatotropic function is mandatory.

MeSH Terms
6-Ketoprostaglandin F1 alpha/biosynthesis Angiotensin II/pharmacology Animals Antibodies/immunology Coronary Circulation/drug effects Endothelium, Vascular/drug effects,physiopathology Growth Hormone/deficiency Growth Hormone-Releasing Hormone/immunology Growth Substances/pharmacology Immunization, Passive In Vitro Techniques Male Myocardial Ischemia/metabolism,physiopathology,prevention & control Myocardial Reperfusion Injury/metabolism,physiopathology,prevention & control Myocardium/metabolism Oligopeptides/pharmacology Rats Rats, Sprague-Dawley Vasoconstrictor Agents/pharmacology Ventricular Pressure/drug effects
Chemicals
Antibodies Growth Substances Oligopeptides Vasoconstrictor Agents hexarelin Angiotensin II 6-Ketoprostaglandin F1 alpha Growth Hormone Growth Hormone-Releasing Hormone
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
De Gennaro Colonna V
Department of Pharmacology, Chemotherapy and Medical Toxicology, University of Milan, Italy.
Rossoni G
Bernareggi M
Müller E E
Berti F
Article Info
Journal
European journal of pharmacology
Abbr.
Eur J Pharmacol
ISSN
0014-2999
Published
1997-09-10
Pages
201-7
Language
English
Region
Netherlands
NLM ID
1254354
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com